logo
  

Pinnacle West Capital Q2 Profit Declines, Backs 2015 Outlook - Quick Facts

Energy holding company Pinnacle West Capital Corp. (PNW) reported second-quarter net income to common shareholders of $122.9 million or $1.10 per share, compared to $132.5 million or $1.19 per share in the prior-year quarter.

On average, 14 analysts polled by Thomson Reuters expected the company to report earnings of $1.23 per share for the quarter. Analysts' estimates typically exclude special items.

Operating revenues for the quarter decreased to $890.65 million from $906.26 million in the comparable quarter last year, while six analysts expected revenue of $933.63 million for the quarter.

Looking ahead to fiscal 2015, the company continues to expect on-going consolidated earnings within a range of $3.75 to $3.95 per share. Analysts expect the company to report fiscal 2015 earnings of $3.85 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT